T Shirasaka

Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides.

T Shirasaka, Mark F. Kavlick, Takamasa Ueno et al. · Proceedings of the National Academy of Sciences · 1995 · 390 citations

Life Sciences, Pharmacology, Molecular Virology +16

Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells.

Wen Gao, T Shirasaka, David G. Johns et al. · Journal of Clinical Investigation · 1993 · 232 citations · Full text

Medicine, Pharmacology, Cellular Metabolism +7

Successful Efavirenz Dose Reduction in HIV Type 1-Infected Individuals with Cytochrome P450 2B6 *6 and *26

Hiroyuki Gatanaga, Tsunefusa Hayashida, K. Tsuchiya et al. · Clinical Infectious Diseases · 2007 · 222 citations

Medicine, Pharmacokinetics, Pharmacology +17

Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: an in vitro comparative study.

T Shirasaka, Robert Yarchoan, Maggie O’Brien et al. · Proceedings of the National Academy of Sciences · 1993 · 132 citations

Medicine, Infectious Diseases, Pharmacology +13

In vitro anti-human immunodeficiency virus (HIV) activities of transition state mimetic HIV protease inhibitors containing allophenylnorstatine

Seiji Kageyama, Tsutomu Mimoto, Yasuhiko Murakawa et al. · Antimicrobial Agents and Chemotherapy · 1993 · 111 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +11